Stock Details
REGN is Regeneron Pharmaceuticals, Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 631.61$. Average daily volumn in 3 months 695.08k. Market cap 65.40B



Stock symbol : REGN. Exchange : NasdaqGS. Currency : USD
Lastest price : 595.40$. Total volume : 387.81k. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Regeneron Pharmaceuticals, Inc. (REGN)
Last Price
595.40$
Change
4.27
Volume
387.81k

Previous Close591.13
Open587.76
Day Range586.17-597.00
Bid593.80 x 1k
Ask595.49 x 800
Volume387.81k
Average Volume695.08k
Market Cap65.4B
Beta0.24
52 Week Range538.01-747.42
Trailing P/E8.39
Foward P/E13.75
Dividend (Yield %)N/A
Ex-Dividend DateN/A



Financial Details


According to Regeneron Pharmaceuticals, Inc.'s financial reports the company's revenue in 2021 were 16.07B an decrease( +100%) over the years 2020 revenue that were of 8.5B. In 2021 the company's total earnings were 8.08B while total earnings in 2020 were 3.51B( +166.67%).


Loading ...



Organization

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vei... n occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Market Cap:
65.40B
Revenue:
16.07B
Total Assets:
25.43B
Total Cash:
2.89B



News about "Regeneron Pharmaceuticals, Inc."

fifth-third-bancorp-sells-337-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn-image

Fifth Third Bancorp Sells 337 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Source from : Defense World - 10 hours ago

Fifth Third Bancorp decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 2.6% during the 1st quarter, according to its most recent filing with the SEC. The ...See details»


spire-wealth-management-has-483000-stock-position-in-regeneron-pharmaceuticals-inc-nasdaqregn-image

Spire Wealth Management Has $483,000 Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Source from : Defense World - 11 hours ago

Spire Wealth Management reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 17.2% in the first quarter, according to its most recent Form 13F filing with ...See details»


regeneron-completes-purchase-of-sanofis-stake-in-libtayo-cemiplimab-image

Regeneron Completes Purchase of Sanofi's Stake in Libtayo® (cemiplimab)

Source from : WFMZ-TV - 1 days ago

Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions ...See details»


gateway-investment-advisers-llc-sells-153-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn-image

Gateway Investment Advisers LLC Sells 153 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Source from : ETF Daily News - 5 days ago

Gateway Investment Advisers LLC lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 13.9% in the first quarter, according to the company in its most recent ...See details»


ritholtz-wealth-management-grows-stake-in-regeneron-pharmaceuticals-inc-nasdaqregn-image

Ritholtz Wealth Management Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Source from : ETF Daily News - 4 days ago

Ritholtz Wealth Management boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 10.4% in the 1st quarter, according to its most recent filing with the Securities and ...See details»


Regeneron Pharmaceuticals Inc - Stock Quote REGN

Source from : Morningstar%2c Inc. - 19 days ago

Using our capsule system, we think that AbbVie, Amgen, Biogen, Johnson & Johnson, and Vertex Pharmaceuticals have the largest excessive deviations from cost-effective pricing for a significant ...See details»


regenerons-eylea-sbla-for-16-week-dosing-regimen-in-diabetic-retinopathy-accepted-for-fda-review-image

Regeneron's EYLEA SBLA For 16-week Dosing Regimen In Diabetic Retinopathy Accepted For FDA Review

Source from : Nasdaq - 3 days ago

(REGN) said Wednesday that the U.S. Food and Drug Administration has accepted for review the EYLEA (aflibercept) Injection supplemental Biologics License Application or sBLA for an every 16-week 2 mg ...See details»


5-top-biotech-stocks-to-watch-in-july-2022-image

5 Top Biotech Stocks To Watch In July 2022

Source from : Nasdaq - 2 days ago

With all this in mind, here are five of the top biotech stocks to note in the stock market today. First up, we have the integrated biotech company, Regeneron Pharmaceuticals. Essentially, the company ...See details»


Regeneron: FDA to Review Extended Eylea Regimen in Diabetic Retinopathy >REGN

Source from : MarketWatch - 3 days ago

By Colin Kellaher Regeneron Pharmaceuticals Inc. on Wednesday said the U.S. Food and Drug Administration will review its application seeking approval of ...See details»


Regeneron Pharmaceuticals, Inc.'s (REGN) Management Presents at Goldman Sachs 43rd Annual Global Healthcare Conference (Transcript)

Source from : Seeking Alpha - 18 days ago

Really pleased to have the Regeneron team with us ... we did end up buying Checkmate Pharmaceuticals about a month ago, which for the three years that we’ve been in existence, actually going ...See details»


Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

Source from : Business Insider - 1 days ago

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.See details»


regeneron-regn-eylea-sbla-for-extended-regimen-accepted-image

Regeneron (REGN) Eylea sBLA for Extended Regimen Accepted

Source from : Yahoo Finance - 2 days ago

FDA accepts Regeneron's (REGN) application seeking label expansion for Eylea for an extended period in patients with diabetic retinopathy.See details»


Regeneron to gain exclusive rights to signature medicine from French collaborator

Source from : Times Union - 28 days ago

RENSSELAER – Regeneron Pharmaceuticals Inc. amended an agreement with Sanofi Biotechnology that will grant it exclusive worldwide development, commercialization and manufacturing rights to its ...See details»


when-the-price-of-regeneron-pharmaceuticals-regn-talks-people-listen-image

When the Price of Regeneron Pharmaceuticals REGN Talks, People Listen

Source from : news.stocktradersdaily - 12 days ago

Short REGN under 621.55, target n/a, stop loss @ 623.35 Details The technical summary data is suggesting a short of REGN as it gets near 621.55, but the downside target is not available from the ...See details»